Skip to main
XAIR

XAIR Stock Forecast & Price Target

XAIR Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Beyond Air is a commercial-stage medical device and biopharmaceutical company that has developed a unique and precise delivery system utilizing nitric oxide from ambient air called LungFit. With its innovative product and technology, the company has potential to capitalize on the growing market for NO therapy, particularly in the treatment of respiratory diseases. The proposed acquisition of NeuroNOS adds another promising platform to Beyond Air's portfolio, demonstrating their commitment to growth and expansion through strategic partnerships. Additionally, the potential for significant monetary gain through milestone payments and equity ownership in the acquiring entity adds further value to the company.

Bears say

Beyond Air is undergoing a transition to drive commercialization and revenue generation, signaled by the replacement of former CEO Steve Lisi with Chief Commercial Officer Robert Goodman. This change suggests that the Board is pushing for a shift towards a story focused on commercial execution, customer deployment, and international expansion. The termination of a proposed agreement and potential divestiture of the NeuroNOS platform has no impact on the company's overall strategic objective, and management remains focused on advancing their core product LungFit. However, there are financial and operational risks to consider, including the company's reliance on third-party partnerships and their ability to successfully commercialize and expand in the market.

XAIR has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beyond Air Inc (XAIR) Forecast

Analysts have given XAIR a Strong Buy based on their latest research and market trends.

According to 1 analysts, XAIR has a Strong Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beyond Air Inc (XAIR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.